T.Man Pharmaceutical Co., Ltd. (TMAN) began trading on the first day, opening above the subscription price of 2.40 baht, an increase of 14.72%. TMAN has a paid-up registered capital after the IPO of 300.00 million baht, with a par value of 0.75 baht per share. It offers to sell ordinary shares to the public for the first time, totaling 102 million shares, consisting of 71.43 million newly issued ordinary shares and 30.57 million existing ordinary shares of TKW Capital Limited, to persons at the discretion of the underwriter, institutional investors, benefactors of the company, employees of the company and its subsidiaries, and persons related to the company, between 10-11 and 15 October 2024 at a price of 16.30 baht per share, totaling 1,164.31 million baht in new shares, and a securities value at the IPO price of 6,520.05 million baht, with Kasikorn Securities Public Company Limited acting as financial advisor and underwriter for the distribution of ordinary shares.

Mr. Prapol Thanachotephan, Chief Executiv
e Officer of T.Man Pharmaceutical PCL, revealed that TMAN is committed to creating innovations and effective products to improve the quality of life. With over 50 years of accumulated knowledge and experience, combined with research and development, TMAN is able to develop quality products that meet consumer needs for both treatment and disease prevention, as well as strengthen the brand. TMAN plans to use most of the raised funds to expand and improve production efficiency to support future business growth plans.

TMAN’s major shareholders after the IPO are the Thanachotphan family, which holds a total of 74.5% of the shares. The company has a dividend payment policy of no less than 30% of net profit according to the company’s separate financial statements after deducting corporate income tax and all types of reserves as specified by law and the company’s regulations, taking into account various factors for the benefit of the company and its shareholders.-513-Thai News Agency

Source: Thai News Agencyl